BioSpace News Archive

Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as a single booster dose at least two months following primary or booster vaccination.

Marvel Biosciences Inc. (TSXV: MRVL) (the “Company” or “Marvel”) highlights recent research indicating a link between non-alcoholic steatohepatitis (NASH) and Alzheimer’s Disease (AD), two programs its lead asset, MB-204 are targeting.

CooperCompanies announced financial results for its fiscal third quarter ended July 31, 2022.

ICON plc, a world-leading healthcare intelligence and clinical research organisation, announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022.

Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), will participate in the following September 2022 conferences.

Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II trial of its Wuhan S-only construct before the market open on Thursday, September 1, 2022.

Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced the closing of a definitive asset purchase agreement under which Flagship Biosciences, Inc. has acquired the Company’s Pharma Services business (Interpace Pharma Solutions).

Adicet Bio, Inc. announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022.

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first half of 2022 and provided a summary of recent corporate highlights.

Hevolution Foundation, a non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science announces the results of $2 Million in matching funding for a program from Impetus Grants, a non-profit science funding organization focused on longevity research.